Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Drug Profile

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; GDNF therapy; Glial-cell-line-derived neurotrophic factor stem cell therapy - BrainStorm Cell Therapeutics; MSC-NTF; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program one

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Preclinical Autistic disorder; Huntington's disease; Multiple sclerosis; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 28 Aug 2017 Phase-III clinical trials in Amyotrophic lateral sclerosis in USA (Intrathecal) (NCT03280056)
  • 15 May 2017 BrainStorm Cell Therapeutics plans to access Health Canada's early access pathway with the support of Centre for Commercialization of Regenerative Medicine for treatment of patients with Amyotrophic lateral sclerosis, for authorised distribution of NurOwn® in Canada
  • 15 May 2017 BrainStorm Cell Therapeutics enters into a Memorandum of Understanding with Ichilov Hospital to make NurOwn® available to patients with Amyotrophic lateral sclerosis under Hospital Exemption regulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top